[1] Nutescu EA, Crivera C, Schein JR, et al. Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events [J]. International journal of clinical practice, 2015, 69(3): 321-7. [2] Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism [J]. Jama, 2014, 311(7): 717-28. [3] Tawfik KM, Moustafa YM, El-Azab MF. Neuroprotective mechanisms of sildenafil and selenium in PTZ-kindling model: implications in epilepsy [J]. European journal of pharmacology, 2018. [4] Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease [J]. Nature reviews Cardiology, 2011, 8(9): 502-12. [5] Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism [J]. Current medical research and opinion, 2010, 26(10): 2465-73. [6] Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis [J]. European heart journal, 2015, 36(10): 605-14. [7] Taherkhani M, Hashemi SR, Hekmat M, et al. Thrombolytic Therapy for Right-Sided Mechanical Pulmonic and Tricuspid Valves: The Largest Survival Analysis to Date [J]. Texas Heart Institute journal, 2015, 42(6): 543-7. [8] Ali MR, Salim Hossain M, Islam MA, et al. Aspect of thrombolytic therapy: a review [J]. TheScientificWorldJournal, 2014, 2014: 586510. [9] Pannucci CJ, Diaz JA, Wahl WL. Temporal changes in deep venous thrombosis risk after electrical injury [J]. Journal of burn care & research : official publication of the American Burn Association, 2011, 32(3): 442-6. [10] Geddings J, Aleman MM, Wolberg A, et al. Strengths and weaknesses of a new mouse model of thrombosis induced by inferior vena cava stenosis: communication from the SSC of the ISTH [J]. Journal of thrombosis and haemostasis : JTH, 2014, 12(4): 571-3. [11] Martin AC, Le Bonniec B, Fischer AM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis [J]. International journal of cardiology, 2013, 168(4): 4228-33. [12] Byrnes JR, Wolberg AS. New findings on venous thrombogenesis [J]. Hamostaseologie, 2017, 37(1): 25-35. [13] Keller K, Prochaska JH, Coldewey M, et al. History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism [J]. Thromb Res, 2015, 136(5): 899-906. [14] Virchow RC. Report on the Typhus Epidemic in Upper Silesia [J]. American Journal of Public Health, 2006, 96(12): 2102-5. [15] Diaz JA, Alvarado CM, Wrobleski SK, et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse [J]. Thromb Haemost, 2013, 109(6): 1158-69. [16] Diaz JA, Wrobleski SK, Hawley AE, et al. Electrolytic inferior vena cava model (EIM) of venous thrombosis [J]. J Vis Exp, 2011, (53): e2737. [17] Ma Q, Zhou Y, Nie X, et al. Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents [J]. Angiology, 2012, 63(5): 330-5. [18] Gray D. Thrombolysis: past, present, and future [J]. Postgraduate medical journal, 2006, 82(968): 372-5. [19] Adivitiya, Khasa YP. The evolution of recombinant thrombolytics: Current status and future directions [J]. Bioengineered, 2016, 8(4): 331-58. [20] Wang X, Gkanatsas Y, Palasubramaniam J, et al. Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis [J]. Theranostics, 2016, 6(5): 726-38. [21] Martini WZ. Fibrinogen availability and coagulation function after hemorrhage and resuscitation in pigs [J]. Mol Med, 2011, 17(7-8): 757-61. [22] Kassner A, Merali Z. Assessment of Blood-Brain Barrier Disruption in Stroke [J]. Stroke, 2015, 46(11): 3310-5. [23] Shimada Y, Shimura H, Tanaka R, et al. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator [J]. PloS one, 2018, 13(5): e0198039. [24] Moser M, Kohler B, Schmittner M, et al. Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase [J]. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1998, 9(6): 455-63.
|